ALLO - CIK 0001737287
Allogene Therapeutics, Inc. (ALLO) reported revenue of $0.00 for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $0.00 | -100.0% |
| FY 2024 | $22.00K | -76.8% |
| FY 2023 | $95.00K | -39.1% |
| FY 2022 | $156.00K | -99.9% |
| FY 2021 | $114.09M | - |
| FY 2020 | $0.00 | - |
| FY 2019 | $0.00 | - |
Allogene Therapeutics, Inc. (ALLO) reported revenue of $0.00 for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2019 and fiscal 2025, Allogene Therapeutics, Inc.'s revenue grew from $0.00 to $0.00.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.